Mefloquine HydrochlorideThird Party Manufacturing in India

Mefloquine Hydrochloride is a 4-quinolinemethanol antimalarial agent structurally related to quinine. It acts primarily by interfering with the parasite's ability to detoxify heme within the digestive vacuole of the malaria parasite. When the Plasmodium parasite invades red blood cells, it degrades haemoglobin as a source of amino acids, releasing free heme which is toxic to the parasite. The parasite normally polymerises this toxic heme into inert hemozoin crystals through a process called heme polymerase activity. Mefloquine binds to free heme and forms toxic complexes that inhibit hemozoin formation, causing oxidative damage to the parasite's membranes and organelles. The drug is active against the erythrocytic stages of all four human malaria species, including multidrug-resistant strains of Plasmodium falciparum. It does not kill gametocytes but does reduce their transmission potential. Mefloquine is well absorbed orally, has a very long elimination half-life of two to three weeks, and concentrates in red blood cells and tissues. Its prolonged half-life allows for weekly dosing in prophylaxis. The drug is effective against chloroquine-resistant falciparum malaria and is used both for treatment of acute uncomplicated malaria and for long-term prophylaxis in travellers to endemic regions.

Therapeutic Uses

Mefloquine Hydrochloride is prescribed for the treatment of:

• Acute uncomplicated malaria caused by Plasmodium falciparum: Particularly effective against chloroquine-resistant strains, making it a critical drug in regions with high antimalarial resistance.
• Malaria prophylaxis: Recommended for travellers to malaria-endemic regions where chloroquine resistance is prevalent, with a convenient once-weekly dosing schedule.
• Mixed malaria infections: Effective against Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae in addition to falciparum malaria.
• Standby emergency treatment: Used as a self-administered treatment option for travellers in remote areas who cannot access immediate medical care.

Why Manufacturers Choose Mefloquine Hydrochloride

Mefloquine Hydrochloride is listed on the WHO Model List of Essential Medicines and remains a cornerstone drug for malaria prophylaxis and treatment in regions with multidrug-resistant malaria. The molecule has a well-established synthetic route and is manufactured to strict pharmacopoeial standards (USP, BP, IP). Indian manufacturers benefit from consistent global demand driven by international travel and military procurement programmes. The long shelf life and stability of Mefloquine Hydrochloride tablets under tropical conditions make them ideal for stockpiling and export to malaria-endemic countries in Africa and Southeast Asia. This makes Mefloquine Hydrochloride one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.